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ERDIL French Study GroSummary Rationale: The Global Initiative for Chronic Obstructive Lung Disease
guidelines recommend bronchodilator reversibility testing to guide treatment
decisions. This study evaluated the relationship between the change in forced
expiratory volume in 1 s (FEV1) with salbutamol or formoterol and the clinical effects
of a 4-week formoterol (Foradils) treatment.
Methods: At Visit 1, patients (n ¼ 448) with stable chronic obstructive pulmonary
disease took an FEV1 reversibility test using 200mg salbutamol via a metered dose inhaler.
At Visit 2 (Day 0), an FEV1 reversibility test was performed using formoterol via a dry-
powder inhaler (Aerolizers). Patients then received formoterol 12mg twice daily until Visit
3 (Day 21–30), when a further formoterol FEV1 reversibility test was performed. Clinical
parameters included FEV1, symptom questionnaires and rescue medication use.
Results: There was no significant relationship between the immediate change in FEV1
with salbutamol and the absolute change from baseline in FEV1, symptom scores or rescue
medication use after a 4-week formoterol treatment. Relative immediate change in FEV1
with formoterol was correlated with change in rescue medication use (P ¼ 0:02) and FEV1
at Visit 3 (Po0:001). Total reversibility in FEV1 with formoterol (post-dose Visit 3–pre-dose
Visit 2) was correlated with all treatment efficacy variables (Po0:01).
Conclusions: Immediate salbutamol reversibility testing, as performed under these
study conditions, failed to predict the clinical efficacy of formoterol. Total reversibility
after 4 weeks of formoterol treatment may be a better predictor of clinical benefits of
long-term bronchodilator therapy.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Bronchodilators are central to the symptomatic
management of chronic obstructive pulmonary dis-
ease (COPD), recommended by the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guide-
lines,1 and may be prescribed on an as-needed or
regular basis. The choice of bronchodilator treatment
is generally based on the physician’s assessment of
the patient’s response to short-acting b2-agonists.
The GOLD guidelines recommend the use of bronch-
odilator reversibility testing for COPD diagnosis and
as a guide to treatment decisions. Several definitions
of partially reversible COPD are used, e.g. that of the
American Thoracic Society (ATS) (X15% increase in
baseline forced expiratory volume in 1 s (FEV1) within
15–30min of inhaling salbutamol) and that of the
European Respiratory Society (ERS)/Socie´te´ de Pneu-
mologie de Langue Franc-aise (X12% increase in
predicted FEV1 and X200mL increase after salbuta-
mol inhalation).2–4 While reversibility testing is
recommended in the guidelines, it is generally
acknowledged, however, that patients who do not
show a significant FEV1 response to a bronchodilator
reversibility test may still benefit symptomatically
from bronchodilator treatment (ATS, GOLD, etc.).
In addition, reversibility tests in COPD have low
reproducibility as the FEV1 response can vary
depending on the drug used and the method of
inspiratory manoeuvre preceding the test.5–7 A
number of studies have shown that reversibility
testing with short-acting b2-agonists may not be the
most accurate means of predicting the efficacy of
long-acting b2-agonist treatment.
8–10 For example,
Cazzola et al.8 found that reversibility to salbutamol
was not an accurate means of predicting broncho-
dilation after salmeterol treatment. Likewise, Mah-
ler11 showed improvements in lung function and
reductions in the severity of dyspnoea with both
salmeterol and ipratropium, in a subgroup of
patients who exhibited irreversibility to salbutamol.
There is currently a need for a standardised
reversibility test, which can be used to predict the
clinical benefit of long-term bronchodilator treatment.
The aim of this study was to evaluate the relationship
between reversibility tests using salbutamol or for-
moterol and the clinical effect of a 4-week treatment
with formoterol.Materials and methods
Patients
All patients were aged X40 years, with stable
COPD according to ATS criteria (1995). They wereto be current or previous smokers (420 pack-years)
with an FEV1p70% of predicted and an FEV1/
FVCo88% or 89% of predicted value in men and
women, respectively. Patients were excluded if
they had a history of asthma, other clinically
significant disease or respiratory tract infection,
or had been hospitalised for a COPD exacerbation in
the month prior to the study or during the
preliminary period. Patients receiving non-potas-
sium-sparing diuretics, b-blockers, quinidine or
quinidine-like antiarrhythmics, tricyclic antide-
pressants, serotonin reuptake inhibitors, or mono-
amine oxidase inhibitors were also ineligible for
enrolment. Bronchodilator treatments were
stopped before Visit 1 according to the following
scheme. Short-acting b2-agonists were stopped 6 h
prior to Visit 1; anticholinergics, long-acting b2-
agonists, fixed combinations of short-acting antic-
holinergic and b2-agonist were stopped 12 h prior to
Visit 1; and theophylline and other xanthine
derivatives were stopped 36 h prior to Visit 1.
Treatment with concomitant inhaled or nasal
corticosteroids was allowed if patients were on a
stabilised regimen. However, patients who had
received systemic corticosteroids or fixed combina-
tions of inhaled long-acting b2-agonist and corti-
costeroid within the previous month or who
required long-term oxygen treatment were ex-
cluded.
Written informed consent was provided by all
enrolled subjects and the study was conducted in
accordance with the latest revisions to the Declara-
tion of Helsinki and with local ethics committee
approval.Study design
This was a multicentre open-label study, which
included three visits. At Visit 1 (Day 30 to 14),
patients were assessed for eligibility and under-
went a reversibility test with FEV1 measurements
before and 15–30min after salbutamol 200 mg
delivered via a pressurised metered-dose inhaler
(100 mg/puff; Ventolines, GlaxoSmithKline, Marly
le-Roi, France). Patients were also issued with
study self-assessment diaries to record COPD
symptoms, rescue medication use and morning
pre-dose peak expiratory flow (PEF; measured using
a standard Mini-Wright peak flow meter). According
to a symptom questionnaire already used in
previous studies,12,13 patients scored the following
six symptoms on a four-point scale (0 ¼ best to
3 ¼ worst) up to a maximum of 18 per day: ability
to perform usual daily activity, breathlessness over
the past 24 h, waking at night due to respiratory
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sputum production. Between Visits 1 and 2, the
only bronchodilator allowed was on-demand salbu-
tamol. At Visit 2 (Day 0), a reversibility test was
carried out with FEV1 measurements before and
15–30min after formoterol 12 mg delivered via a
dry-powder inhaler (Foradils Aerolizers, Novartis
Pharma, Basel, Switzerland). The single dose of
12 mg of formoterol was selected because it induces
a maximal bronchodilation similar to that of 200 mg
of salbutamol,14,15 which is the dose generally used
for reversibility testing in clinical practice.8,16,17
Patients then received formoterol 12 mg twice
daily (b.i.d.) between Visits 2 and 3 (minimum
duration 21 days, maximum duration 30 days). No
other bronchodilator treatment was allowed, ex-
cept on-demand salbutamol. At Visit 3, an FEV1
reversibility test was performed before and
15–30min after inhalation of formoterol 12 mg.
Bronchodilator reversibility tests were performed
at the same time of day at each visit.Definitions and efficacy variables
All spirometry assessments were performed in
triplicate with the highest values being used for
analysis. Spirometers were calibrated before each
visit. FEV1 reversibility data were presented as
both the absolute difference (absolute change in
FEV1 in L) and the relative changes (in percentage
of the baseline value and in percentage of the
predicted value). For the total FEV1 reversibility
test, the difference between the pre-dose mea-
surement at Visit 2 and the post-dose measurement
at Visit 3 was calculated. In contrast to the total
reversibility test, standard reversibility test mea-
sured at each visit was termed immediate reversi-
bility test. The primary efficacy variable was the
relationship between immediate change in FEV1
with salbutamol at Visit 1 and the efficacy variables
(change in baseline FEV1, PEF, symptom scores and
rescue medication use) following the 4-week
formoterol treatment. Secondary efficacy variables
included the relationship between immediate (Visit
2) or total (Visit 3) change in FEV1 with formoterol
and the efficacy variables of the 4-week formoterol
treatment, and the relationship between immedi-
ate change in FEV1 with salbutamol (Visit 1) and
formoterol (Visit 2) and total change in FEV1 with
formoterol (Visit 3).Statistical analyses
Reversibility tests and clinical and spirometric
efficacy variables at each visit were recorded usingdescriptive statistics and graphical representations
(mean values are presented7standard deviation
unless otherwise specified). The Wilcoxon’s rank
signed test was used to assess the change in
efficacy variables from the previous visit, and the
McNemar test was used to compare the reversibility
tests at Visits 1 and 2 and total reversibility with
regard to ATS and ERS criteria. Calculation of
correlation coefficients and linear regression mod-
elling were used to explore the relationship
between reversibility and efficacy variables.
All included patients were taken into account in
the safety analysis. Reversibility tests and clinical
and spirometric efficacy variables were described
for all patients with valid baseline reversibility and
a measure of efficacy at Visit 3. Patients with
relative reversibility of FEV1 at baseline of more
than 730% were excluded from the efficacy
analysis to prevent the inclusion of COPD patients
with associated asthma.Results
A total of 448 patients were enrolled in the study
from 262 private practice pulmonologists. Twenty-
eight patients (6.3%) discontinued from the study
prematurely, the main reasons being loss of contact
(2.0% [9/448]), adverse events (AEs) (1.6% [7/
448]), patients no longer met the protocol criteria
(1.1% [5/448]) and withdrawal of consent (0.9% [4/
448]). Thirty-four (7.6%) patients were excluded
from the per-protocol population due to relative
reversibility of FEV1 of more than 730%. Patient
demographics and baseline spirometry values are
shown in Table 1. The majority of patients had
moderate Stage II (58.0%) or severe Stage III COPD
(32.4%) according to the GOLD definition.
The breakdown of patients receiving long-term
bronchodilator treatment before the start of the
study were as follows: fixed combination of
salbutamol and ipratropium bromide (22.3%), fixed
combination of fenoterol and ipratropium bromide
(15.8%), salmeterol (8.5%), theophylline (3.8%),
ipratropium bromide (2.0%), oxitropium bromide
(0.4%), and short-acting b2-agonists (43.3%). In-
haled corticosteroids were used by 48.0% of
patients during the study.
Reversibility tests
The mean FEV1 absolute values (7SD) observed
before and after bronchodilator at each visit are
shown in Table 2 and the mean values of reversi-
bility in FEV1 at each visit are presented in Fig. 1.
ARTICLE IN PRESS
Table 2 Mean (SD) FEV1 absolute values (L) observed before and after bronchodilator at each visit.
Before bronchodilator After bronchodilator
Visit 1 (salbutamol 200 mg) 1.54 (0.49) 1.71 (0.55)
Visit 2 (formoterol 12 mg) 1.55 (0.56) 1.71 (0.57)
Visit 3 (formoterol 12 mg after a 4-week treatment) 1.62 (0.56) 1.76 (0.59)
Table 1 Patient demographics and baseline characteristics.
Total patients ¼ 448
Male, n (%) 370 (82.6)
Mean age, years (SD) 63.0 (10.7)
Mean pack-years (SD) 37.3 (19.9)
Smoking history
COPD history, mean years (SD) 12.2 (9.4)
Mean FEV1, L (SD) 1.55 (0.48)
Mean FEV1, % predicted (SD) 53.2 (14.2)
Mean FVC, L (SD) 2.57 (0.71)
Mean FVC, % predicted (SD) 69.9 (16.6)
Disease severity (GOLD criterion), n (%)
Stage I: Mild COPD
FEV1X80% of predicted 11 (2.5)
Stage II: Moderate COPD
FEV1X50 and o80% of predicted 260 (58.0)
Stage III: Severe COPD
FEV1X30 and o50% of predicted 145 (32.4)
Stage IV: Very severe COPD
FEV1o30% of predicted 26 (5.8)
Concomitant medication, n (%)
Inhaled corticosteroids 215 (48.0)
Long-term bronchodilators prior to study 212 (47.3)
SD, standard deviation; FEV1, forced expiratory volume in 1 s; FEF, forced expiratory flow; FVC, forced vital capacity; GOLD,
Global initiative for Chronic Obstructive Lung Disease; and COPD, chronic obstructive pulmonary disease.
M. Molimard et al.698The mean (7SD) immediate absolute change in FEV1
after administration of 200 mg salbutamol was
0.1570.13 L (relative reversibility: 10.279.0% of
baseline value, 5.174.6% of predicted value). At
Visit 2, the mean (7SD) immediate absolute change
in FEV1 after administration of 12 mg formoterol was
0.1670.16 L (relative change: 12.0714.0% of base-
line value, 5.575.4% of predicted value), and at
Visit 3, 0.1270.19 L (relative change: 8.8712.8%
of baseline value, 4.376.8% of predicted value).
The total reversibility test with formoterol (differ-
ence between the pre-dose measurement at Visit 2
and the post-dose measurement at Visit 3) showed
a change in FEV1 of 0.2170.26 L (relative change:
16.5719.9% of baseline value, 7.579.1% of pre-
dicted value). A significantly greater number of
patients met the ATS criterion for reversible COPDwith the total formoterol reversibility test than
with the immediate salbutamol reversibility test
(48.2% and 32.2%, respectively, P ¼ 0:008). A
similar difference was observed with the ERS
criterion with 52.4% of patients meeting the
criterion with the total formoterol reversibility
test compared with 34.5% with the immediate
salbutamol reversibility test (Po0:001). The per-
centage of ATS/ERS reversible patients was also
significantly greater with the immediate formoterol
reversibility test (34.3% and 38.1%) than with the
immediate salbutamol reversibility test (Po0:001).
Clinical efficacy variables
The efficacy variables after the 4-week formoterol
treatment are shown in Table 3. Formoterol
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from baseline in daily symptom scores, rescue
medication use, PEF and baseline FEV1 (all
Po0:01).Table 3 Changes in efficacy variables (per protocol pop
Efficacy variable (mean7SD) Baseline
Daily symptom score (0–18 scale) 4.5672
Number of puffs/day of salbutamol 2.372
Peak expiratory flow rate (L/min) 298.979
Baseline FEV1 measured at Visits 2 and 3 (L) 1.5470
SD, standard deviation; and FEV1, forced expiratory volume in 1 s
*Statistically significant change (Po0:01 Wilcoxon’s signed rank
Figure 1 Mean reversibility in FEV1 at Visits 1 (after
salbutamol), 2 and 3 (after formoterol) and total
reversibility (difference post-dose FEV1 at Visit
3baseline FEV1 at Visit 2) expressed in (a) absolute
value (L), (b) percentage of baseline value, and (c)
percentage of predicted value.Reversibility–efficacy correlations
Primary efficacy endpoints
There was no significant relationship between
immediate change in FEV1 with salbutamol and
the absolute change from baseline in FEV1 after the
4-week formoterol treatment (Fig. 2). Similarly, no
significant relationship was found between immedi-
ate change in FEV1 with salbutamol (either absolute
or relative) and symptom scores, rescue medication
use or PEF after the 4-week formoterol treatment
(Table 4).
Secondary efficacy endpoints
The correlations between change in FEV1 with
formoterol and each of the efficacy variables are
shown in Table 4. Relative immediate change in
FEV1 with formoterol significantly correlated with
change in rescue medication use (P ¼ 0:02) and in
baseline FEV1 (Po0.001), but not with symptoms or
PEF. In contrast, relative total change in FEV1 with
formoterol significantly correlated with all the
treatment efficacy variables. Absolute total change
in FEV1 with formoterol was also significantly
correlated with change in symptoms, PEF and
baseline FEV1.
Safety and tolerability
Formoterol was generally well tolerated. At least
one AE was experienced by 16.7% patients (75/448)
and 2.9% of patients (13/448) experienced an AE
suspected to be drug related. Class effects for b2-
agonists included muscle cramps (0.7%, three
patients), tremor (0.4%, two patients), palpitations
(0.2%, one patient) and headache (0.2%, one
patient). Five patients (1.1%) withdrew because
of one or more AEs suspected to be drug relatedulation).
After 4-weeks
formoterol treatment
.88 Difference 0.8372.21* 3.7672.80
.4 Difference 1.371.9* 1.171.7
8.0 Difference +28.3738.2* 326.37102.3
.53 Difference +0.0970.24* 1.6170.55
.
test).
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Figure 2 Relationship between the relative immediate change in FEV1 with salbutamol and the absolute change in the
baseline FEV1 after a 4-week formoterol treatment.
Table 4 Correlation coefficients (P-values) between the absolute and relative (in % of baseline value) changes
in forced expiratory volume in 1 s (FEV1) with salbutamol and formoterol and the changes in efficacy variables
following a 4-week formoterol treatment.
Correlation coefficient (P-value)
Immediate change in FEV1 with
salbutamol
Immediate change in FEV1 with
formoterol
Total change in FEV1 with
formoterol
Variable Absolute Relative Absolute Relative Absolute Relative
k Symptoms 0.018 0.050 0.024 0.002 0.107 0.145
(P ¼ 0:73) (P ¼ 0:34) (P ¼ 0:64) (P ¼ 0:97) (P ¼ 0:047) (P ¼ 0:007)
k Rescue 0.018 0.051 0.061 0.125 0.105 0.150
salbutamol (P ¼ 0:74) (P ¼ 0:34) (P ¼ 0:27) (P ¼ 0:02) (P ¼ 0:057) (P ¼ 0:007)
m PEF 0.040 0.006 0.07 0.086 0.209 0.235
(P ¼ 0:45) (P ¼ 0:91) (P ¼ 0:18) (P ¼ 0:11) (Po0:001) (Po0:001)
m Baseline 0.053 0.036 0.393 0.399 0.691 0.672
FEV1 (P ¼ 0:31) (P ¼ 0:48) (Po0:001) (Po0:001) (Po0:001) (Po0:001)
P-values are related to the test of null Pearson correlation coefficient.
FEV1, forced expiratory volume in 1 s.
M. Molimard et al.700(fine tremor in two patients; sensation of malaise in
one patient; palpitations in two patients; dyspnoea
in one patient; nervousness in one patient). Eight
severe AEs occurred (1.8%): seven of these events
were not suspected to be drug related (cancer in
three patients; bronchospasm in one; infection in
one; accidental thoracic trauma in one; death due
to a sudden cardiorespiratory arrest of unknown
cause in a 75-year-old patient) and one event was
suspected to be drug related (patient with known
coronary heart disease hospitalised for severe
angina, without myocardial infarct).Discussion
The GOLD guidelines state that bronchodilator
reversibility testing may be performed at the time
of diagnosis of COPD to help rule out a diagnosis of
asthma, to establish a patient’s best attainable
lung function, to gauge prognosis, and to assess
potential response to treatment. They go on,
however, to acknowledge the day-to-day variability
of the response, the arbitrariness of the values used
to define a significant response, and the fact that
patients who do not show a significant response to
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term bronchodilator therapy.1 Further doubts as to
the diagnostic and prognostic value of the proce-
dure were raised in two recent publications. The
analysis of data from two studies showed convin-
cingly that the failure to demonstrate a response to
a single bronchodilator challenge did not predict
either a lack of subsequent bronchodilator re-
sponse, or improvements in other variables such
as symptom relief and quality of life with regular
use of bronchodilator therapy.17,18 Similar findings
have been reported in earlier studies.12,13 In the
present study, we have confirmed that, in patients
with stable COPD, immediate reversibility testing
with salbutamol is not useful to predict whether a
patient will benefit from a 4-week period of
treatment with formoterol, in terms either of lung
function or symptomatically.
Our study assessed the predictive value of single
reversibility testing using the bronchodilator for-
moterol. This agent is suitable for use in such a test
because of its rapid onset of action, demonstrably
similar to that of salbutamol in COPD patients.5
Furthermore, formoterol is a full agonist at the b2-
adrenoceptor, allowing a maximal bronchodilator
response to be attained.19 In addition, there is
some evidence to suggest that the response to
formoterol is less affected by the genetic poly-
morphisms in the b2-adrenoceptor that may lead to
variability in the bronchodilator response to salbu-
tamol.20–22
In this study, we used two methods to assess the
predictive value of reversibility testing using for-
moterol. First, we compared the effects of a single
test with the clinical and objective responses
observed during 4 weeks of formoterol treatment
(immediate reversibility test). Immediate reversi-
bility test proved to be predictive of the 4-week
improvement in lung function but did not correlate
with the improvement in clinical symptoms. The
second method was to assess reversibility as the
difference between the baseline value (pre-
bronchodilator) and the value obtained post-
bronchodilator when the test was repeated follow-
ing the short course of treatment with formoterol
(total reversibility test). In contrast, total reversi-
bility test (expressed in absolute values or as
percentage change) was significantly correlated
with both lung function and clinical improvements.
The test is therefore likely to prove relevant for
long-term improvements in exercise capacity and
quality of life, which are largely impacted by the
symptoms of COPD. Furthermore, the total rever-
sibility test identified significantly more patients
who met the ATS/ERS criteria for reversibility than
did the single test using salbutamol. Other studiesevaluating reversibility and other lung function
parameters 15,23 have administered treatments on
an open-label basis. As the main objective was to
evaluate the correlation between reversibility tests
and clinical parameters, and not to compare the
efficacy of salbutamol and formoterol, the open-
label design of this study is unlikely to have
introduced any bias.
The test of total reversibility could be readily
incorporated into the routine assessment and
management of COPD patients. In practice, we
would recommend that baseline spirometry be
performed at the initial assessment, before begin-
ning formoterol treatment, with a second spiro-
metry performed after at least 1 month of
treatment with the same agent, using one capsule
of formoterol 12 mg from the patient’s own treat-
ment. The total reversibility test could help the
physician to confirm the clinical improvement
reported by the patient and provide relevant
information to guide decisions on further treat-
ment. In addition, the use of this test to assess
reversibility will enable the adequate identification
of potentially eligible (reversible) patients who
stand to benefit from long-term bronchodilator
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